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SUMMARY
High titres of pertussis toxin (PT) antibody have been shown to be predictive of recent infection
with Bordetella pertussis. The seroprevalence of standardized anti-PT antibody was determined in
six Western European countries between 1994 and 1998 and related to historical surveillance and
vaccine programme data. Standardized anti-PT titres were calculated for a series of whole-cell and
acellular pertussis vaccine trials. For the serological surveys, high-titre sera (>125 units/ml) were
distributed throughout all age groups in both high- (>90%) and low-coverage (<90%) countries.
High-titre sera were more likely in infants in countries using high-titre-producing vaccines in their
primary programme (Italy, 11.5%; Western Germany, 13.3%; France, 4.3%; Eastern Germany,
4.0%) compared to other countries (The Netherlands, 0.5%; Finland, 0%). Recent infection was
signiﬁcantly more likely in adolescents (10–19 years old) and adults in high-coverage countries
(Finland, The Netherlands, France, East Germany), whereas infection was more likely in children
(3–9 years old) than adolescents in low-coverage (<90%; Italy, West Germany, United Kingdom)
countries. The impact and role of programmatic changes introduced after these surveys aimed at
protecting infants from severe disease by accelerating the primary schedule or vaccinating older
children and adolescents with booster doses can be evaluated with this approach.
INTRODUCTION
Despite the availability of eﬀective vaccines for
several decades, pertussis continues to be a public
health problem in many European countries ; circu-
lating widely in countries with low vaccine coverage
and reportedly re-emerging in other highly vaccinated
populations [1–6].
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In the pre-vaccination era, the majority of the
population was infected before 10 years of age, with
signiﬁcant morbidity and mortality particularly in in-
fants and young children [7].Most European countries
introduced universal infant vaccination with whole-
cell pertussis vaccines during the 1950s. By the 1970s,
with concerns about vaccine safety, several countries
ceased their pertussis control programmes (e.g.
Sweden, West Germany), while others experienced a
dramatic decline in coverage (e.g. the United
Kingdom) [8]. These events stimulated the develop-
ment of acellular vaccines, speciﬁc subcomponents of
the bacterium with a better side-eﬀect proﬁle [9], that
several countries have now introduced [10, 11].
The current epidemiology of pertussis in Europe
relates to this historical diversity of control pro-
grammes. There is a predictable, negative correlation
between vaccine coverage and reported incidence of
pertussis [8]. However, the reasons for the reappear-
ance of pertussis in highly vaccinated populations
(such as the United States, Finland and The
Netherlands) [1–4] are less clear. Reported cases have
often been in adolescents and adults who have been
previously immunized or infected [1, 12, 13] and who
present with atypical or mild clinical features. Two
explanations have been put forward. First, that vac-
cination protects against disease, but less well against
infection and transmission and that pertussis con-
tinues to circulate widely and ‘silently ’ amongst adults
in highly vaccinated populations [7, 14], with cyclical
epidemics every 3–4 years as in the pre-vaccination era
[15, 16]. The recent re-emergence of pertussis is thus
explained by improved case ascertainment due to
better diagnosis of disease in adults and reporting [13,
14]. An alternative explanation is provided by a more
recent analysis which found an increase in the ob-
served inter-epidemic period following mass vacci-
nation, suggesting a reduction in transmission and a
resultant increase in age of infection [16]. Other fac-
tors, which could contribute to the re-emergence of
pertussis in older populations, are waning protection
after vaccination or infection [17] and to a lesser ex-
tent the emergence of antigenic variants of Bordetella
pertussis, resulting in increased susceptibility amongst
previously vaccinated individuals [2, 3].
Whatever the explanation, infection in older per-
sons does seem to be of public health importance.
The extent of infection and the potential disease bur-
den in these older age groups remains inadequately
described and it is suggested that children and teen-
agers can be involved in the spread of pertussis to
unprotected or partially protected infants resulting in
signiﬁcant morbidity [18–22]. Several countries have
thus recently introduced acellular pertussis booster
doses in an attempt to reduce pertussis circulation in
older age groups [11, 23] and indirectly reduce trans-
mission to infants. Others have accelerated their vac-
cination schedules by delivering the primary schedule
at an earlier age in infancy to provide direct protec-
tion [24].
Surveillance tools are critical to monitor the impact
of these interventions. However, routine pertussis
surveillance data has well-recognized limitations re-
lated to variations in clinical and surveillance practice
and a lack of suﬃciently sensitive diagnostic methods.
There is a need for alternative, standardized tools to
evaluate the eﬀectiveness of new prevention strategies.
Recently, de Melker and colleagues demonstrated
that high titres of antibody to pertussis toxin (PT) can
be a sensitive and speciﬁc indicator of recent infection
[25]. In a longitudinal cohort of Dutch patients with
clinically conﬁrmed pertussis infection, the mean time
of persistence of immunoglobulin-G (IgG) PT>100
Dutch units/ml amounted to 4.5 months. Antibody
titres declined to <100 Dutch units in almost all
patients after a period of 12 months, independent of
age and vaccination status. Monitoring the distri-
bution of high-titre sera as a marker for the incidence
of infection in the general population could be a tool
to understand the impact of vaccination and to po-
tentially evaluate programme performance. However,
the age-speciﬁc distribution of high-titre sera depends
upon exposure to both natural pertussis infection
and pertussis immunization; these two factors can
only be disentangled through knowledge of the anti-
PT IgG antibody response to both vaccination and
infection.
In this paper, we document the prevalence of high
titres of anti-PT IgG antibody in large, comparable
serological surveys from sixWestern Europe countries
with various pertussis immunization programmes.
The anti-PT antibody results from each country have
been statistically standardized against a reference
laboratory [26] and the results interpreted together
with standardized immunogenicity data from a variety
of vaccine trials, with knowledge of the country-
speciﬁc historical vaccine schedules, the types of vac-
cines used and the reported vaccine coverage. This
provides a unique opportunity to better understand
the true extent of infection across the population in
each country and to compare the impact of a variety
of intervention strategies.
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METHODS
Vaccine programme history and performance
A questionnaire was distributed to the participating
countries in the European Sero-Epidemiology Net-
work (ESEN) in 1997 to gather data on pertussis
vaccine programmes (including type of vaccine, num-
ber of doses and age of administration). Surveillance
practice including pertussis case deﬁnitions, historical
vaccine coverage and the number of pertussis cases
reported by age group were collected. Some results
have previously been reported [10]. Countries were
divided into two groups [‘high coverage ’ (>90%) and
‘low coverage ’ (<90%)] based on mean reported
coverage in the 15–20 years prior to the serosurvey.
Pertussis incidence rates were calculated based on
oﬃcial notiﬁcations of pertussis infection and annual
population data. Secular trends in pertussis incidence
were examined to identify epidemic years and to esti-
mate the inter-epidemic period. The proportion of
reported cases older than 10 years of age in each epi-
demic year was calculated.
Serum survey collection
Six countries (England & Wales, Finland, France,
Germany, Italy, The Netherlands) undertook collec-
tion and testing of large serum banks for anti-PT IgG
antibody between 1994 and 1998. Details of the
sources of sera and methods of collection have been
described previously [27]. A minimum number of sera
to be collected in each age group was established, with
equal numbers by gender in each age group. The total
numbers of sera tested by each country ranged from
2606 to 7755 (see Appendix). Brieﬂy, two sampling
methods were used: population-based sampling
(The Netherlands) or residual sera submitted to
laboratories for other purposes (the remaining ﬁve
countries). The sera were collected from geographi-
cally diverse sites in each country to provide a reason-
ably representative estimate of the general population
experience.
Information collected on each sample included:
age, gender, date of sampling and geographical infor-
mation. The latter enabled the identiﬁcation of sera
from former East and West Germany.
Standardization: panel distribution and testing
To achieve quantitative comparability of assay results
between countries, the results were standardized using
a previously described methodology [26]. Brieﬂy,
the process involved the creation of a panel of 150
samples: 50 negative sera (<5 ESEN units/ml), 12
low positive (5–10 ESEN units/ml) and 88 positive
(>10 ESEN units/ml) sera for PT IgG antibody
by the reference laboratory (University of Palermo,
Italy). Forty-two of these sera were considered to be
high-titre positive (>125 ESEN units/ml).
The reference panel was distributed to the national
laboratory in each participating country, to be tested
with their usual quantitative method (enzyme im-
munoassay) for serum anti-PT IgG antibody. All
laboratories (except The Netherlands) used the US
Food and Drug Administration (FDA) standard
serum (lot HRP3) as an external control to calibrate
their test assays. The panels were tested twice: once
before main serum bank testing to evaluate test per-
formance and again during main serum bank testing.
Country-speciﬁc standardization equations were cal-
culated by regressing the local results of panel testing
against those of the reference laboratory.
Main serum survey testing
Each main national serum survey was tested using the
same validated assay method as the reference panel.
The country-speciﬁc standardization equations were
used to convert local quantitative results of serum sur-
vey into standardized reference laboratory unitage.
Details of the country-speciﬁc assays and standardiz-
ation methodology have been described recently [26].
The reference laboratory cut-oﬀs were used to
classify standardized results. The minimum limit of
detection (MLD) was deﬁned as 5 units/ml. The cut-
oﬀ chosen to indicate likelihood of recent infection
was 125+ ESEN units/ml (equivalent to 100 Dutch
units/ml). This has been shown to indicate with high
probability, infection from within 4 weeks of disease
onset up to 1 year after [25, 26]. A further cut-oﬀ of
62.5 ESEN units (equivalent to 50 Dutch units) was
also used, which shows infection in the previous 12
months with high probability [25, 26].
High-titre re-testing
A subsample of 100 high-titre sera (mostly >62.5
ESEN units) was selected from the main serosurvey in
each country for re-testing by the Italian reference
laboratory. These were used to validate the country-
speciﬁc standardization equations obtained from
testing the main reference panel and to provide
more information for the quantitative inter-country
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comparisons. These results have been previously
described [26]. In this paper, the German high-titre
re-tests suggested the standardized titres should have
been even higher, and that the proportion of high-titre
sera described in the current paper are probably an
underestimate.
PT antibody levels post-vaccination
High PT titres are produced by natural infection for
which we use a cut-oﬀ of 125 ESEN units. To deter-
mine whether such high titres could be produced by
vaccination, we re-analysed data from four trials of
a variety of whole-cell and acellular vaccines in the
United Kingdom and standardized the results into
comparable ESEN unitage [24, 28–30]. These allowed
a direct comparison with the results of the present
serosurvey, and thus, determine if anti-PT antibody
levels due to vaccination were similar to those due to
natural infection.
In a study by Miller [28], a phase II randomized
clinical trial was undertaken to compare the immuno-
genicity of three acellular vaccines [manufactured by
Wyeth-Lederle (Maidenhead, Berks, UK), Connaught
(Willowdale, ON, Canada), Aventis-Pasteur (Maiden-
head, Berks, UK)] and a whole cell vaccine (Well-
come). Sera were sampled 4–6 weeks and 12–18
months after completion of a three-dose primary
course in infancy. In a second study by Bell [29], the
immunogenicity of a whole-cell vaccine (Pasteur-
Me´rieux, Wellcome, Beckenham, Kent, UK) was
measured in 146 infants, 4–6 weeks following immu-
nization. In a third study by Miller [30], the immuno-
genicity of a booster dose of whole-cell vaccine
(Wellcome) was measured in 96 children, aged 4–5
years, 6 weeks after vaccination. In a ﬁnal study by
Miller [24], the immunogenicity of a pre-school booster
of four acellular vaccines was measured in 330
(Aventis-Pasteur), 134 (SmithKline Beecham,Welwyn
Garden City, Herts, UK), 181 (Chiron Biocine CA,
USA) and 116 (Wyeth-Lederle) children, aged 4–5
years with samples taken 4–6 weeks after vaccination.
The Centre for Applied Microbiology and
Research (CAMR), UK, assayed the sera from the
four trials for anti-PT IgG antibodies, using enzyme-
linked immunosorbent assay. A two-step standardiz-
ation process was used. First, to convert CAMR units
to UK units, a total of 387 sera were tested by both
CAMR and the Central Public Health Laboratory
(241 samples taken from the general population and
146 from individuals presenting with cough illness).
The standardization equation was derived using
the technique described above (details available on
request). Secondly the UK results were converted into
ESEN equivalent units using the UK standardization
equation derived from reference panel testing as part
of the ESEN project [26].
Statistics
All data were entered and managed in Microsoft
Excel (Version 7). Statistical analysis was undertaken
in Epi-Info, version 6.04b (CDC, Atlanta, GA, USA)
and STATA, version 7.0 (StataCorp, TX, USA). Pro-
portions were compared using the x2 test or Fisher’s
exact test as appropriate. For inter-country com-
parisons across age groups, direct standardization
was undertaken using the European standard popu-
lation [31].
RESULTS
Vaccine programme history
All six ESEN countries introduced pertussis vacci-
nation with whole-cell vaccine during the 1950s and
1960s (Table 1). A variety of whole-cell vaccines were
used: some produced by national centres (Finland,
The Netherlands and East Germany until 1989), the
remainder by a variety of commercial manufacturers.
All six countries had three-dose primary pro-
grammes at the time of the serosurvey: Finland, The
Netherlands and Germany had a 3, 4, 5 months
schedule; Italy a 3, 5, 7 months schedule ; France and
England & Wales, an accelerated schedule delivered
at 2, 3, 4 months. Two countries (England & Wales,
Italy) had no booster dose in their routine pro-
gramme. The four remaining countries had a booster
dose administered ranging from the age of 11 months
(The Netherlands), 12–15 months (Germany), 18
months (France) to 24 months (Finland). France
introduced a second booster dose for the 11–13 years
age group in 1998, the year of the serosurvey.
For the primary course at the time of the sero-
survey, four countries (Finland, England & Wales,
France, The Netherlands) used solely whole-cell
vaccine. In Finland and The Netherlands, the vac-
cine was produced by national manufacturers; in
England & Wales by a variety of commercial manu-
facturers (includingAventis-Pasteur,Wellcome-Evans
and SmithKline Beecham) and in France by Aventis-
Pasteur. The two other countries (Italy, Germany)
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had introduced commercially produced acellular
vaccines for the primary schedule (Lederle and Smith-
Kline Beecham in Germany; Chiron and SmithKline
Beecham in Italy). Germany was also still using
whole-cell vaccine produced by Chiron and Aventis-
Pasteur at the time of the serosurvey.
For the booster doses, Finland and The Nether-
lands used nationally produced whole-cell vaccines.
Germany and France used commercially produced
acellular vaccines (Lederle and SmithKline Beecham
in Germany; Aventis-Pasteur and SmithKline Beech-
am in France).
Reported vaccine coverage levels
Reported vaccine coverage levels for the third dose
of pertussis vaccine (DPT3) measured between 12
and 24 months of age varied dramatically over time
and between country (Figs 1 and 2, Table 2). High
(>90%) coverage levels have been maintained for
more than 20 years in Finland, The Netherlands,
France and East Germany until reuniﬁcation in 1990
(Table 2).
In West Germany and England & Wales, coverage
levels dropped substantially during the 1970s and
1980s [32] (Fig. 2). The programme was ceased in
West Germany in 1975 and only recommenced fol-
lowing reuniﬁcation in 1990. Coverage levels in the
United Kingdom recovered steadily during the 1990s
to reach 94% by 1995, the year of the serosurvey. In
Italy, reported coverage was low with considerable
regional variation in uptake (8–71% in 1991), but
with a recent increase of up to 88% by 1996 [33].
Reported incidence of pertussis
The inter-epidemic period and the age distribution of
cases each epidemic year are outlined in Table 2.
Finland, France and Italy had epidemic years in the
12 months before the survey was conducted, unlike
The Netherlands or United Kingdom. No recent dis-
ease surveillance data was available from united
Germany.
In two of the four historically high-coverage
countries (Finland and the former East Germany),
during the 1970s and early 1980s, a long inter-
epidemic period was observed (up to 10 years)
(Table 2). During the 1990s, regular epidemics were
observed in France, Finland and The Netherlands at
4–5 yearly intervals. In Finland nearly 60% of
reported cases were older than 10 years of age, as were
24% of reported cases in The Netherlands.
In the two historically low-coverage countries
(England & Wales, Italy) for which surveillance data
is available, the inter-epidemic period remained at 4–5
yearly intervals over the past three decades. In both
Table 1. History of pertussis vaccination programme in six ESEN countries
Country
Type of
pertussis-containing
vaccine
Year of
introduction
and cessation
Age of
primary
course
Age of
booster doses
Finland DTP whole cell 1957– 3, 4, 5 mo. 24 mo.
France DTP whole cell 1959– 2, 3, 4 mo. 16–18 mo. until 1998
DTaP acellular 1998– 18 mo., 11–13 yr
West Germany DTP whole cell 1964–76 3, 4, 5 mo. 12–15 mo.
East Germany DTP whole cell 1963–90 3, 4, 5 mo. 3 yr
Germany DTP whole cell 1991–97 3, 4, 5 mo. 12–15 mo.
DTaP acellular 1995– 3, 4, 5 mo. 12–15 mo.
DTaP acellular* 2000– 11–18 yr
Italy DTP whole cell 1964– 3, 5, 7 mo.
DTaP acellular 1995–99 3, 5, 7 mo.
DTaP acellular* 1999– 3, 5, 11 mo. 5–6 yr
The Netherlands DTP whole cell 1952–99 3, 4, 5 mo. 11 mo.
DTP whole cell* 1999– 2, 3, 4 mo. 11 mo.
DTaP acellular* 2001– 4 yr
United Kingdom DTP whole cell 1957–91 3, 5, 10 mo.
DTP whole cell 1991– 2, 3, 4 mo.
DTaP acellular* 2001 4–5 yr
* Introduced into the national programme after the serosurvey was conducted.
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countries, the proportion of cases older than 10 years
of age increased from 6–9% in the period from 1970
to the 1980s to>14% in the 1990s.
PT antibody levels post-vaccination
In infancy, 4–6 weeks after the primary course of the
two whole-cell and all three acellular vaccines, the
standardized geometric mean titres (GMTs) were
well below the 125 ESEN units/ml cut-oﬀ (Table 3).
However, for the whole-cell and the acellular vaccines
produced by Aventis-Pasteur, the estimated pro-
portion of vaccinees with GMTs above 125 units/ml
was 26% and 11% respectively. Twelve to eighteen
months after vaccination, the proportion of vaccinees
estimated to have titres >125 units/ml had declined
to>2% for all four vaccines examined.
At age 4–5 years, 4–6 weeks after a booster dose of
the Wellcome whole-cell vaccine, the estimated pro-
portion of vaccinees with titres above 125 units/ml
was 1%. For the four acellular vaccines, the estimated
proportion of vaccinees with high-titre antibody
levels ranged from 4% (Wyeth-Lederle) to over 30%
(Chiron Biocine).
Prevalence of anti-PT titre by age
Figures 1 and 2 show the distribution of anti-PT titres
by age group, together with the reported DPT3
coverage and the vaccine exposure of each age cohort
in the 12 months prior to the serosurvey. Several
points can be noted: ﬁrst, high titres of anti-PT anti-
body (both>62.5 and>125 units/ml) (Figs 1–3) were
found in all age groups and in each country.
Second, the three countries using high-titre-
producing vaccines (Chiron acellular vaccine or
Aventis-Pasteur whole-cell vaccine) in their primary
schedule had a signiﬁcantly higher proportion of
high-titre sera (125 units/ml) in infants (Italy, 11.5%;
West Germany, 13.3%; East Germany, 4%; France,
4.3%) compared to the two high-coverage countries
using other whole-cell vaccines (reference Italy) : The
Netherlands (0.5%, P<0.001), Finland (0%, P=
0.007).
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Fig. 1. Age-speciﬁc distribution of PT high IgG titres and historical reported DTP3 coverage in four high coverage ESEN
countries.%,>125 units/ml ; , 62.5–125 units/ml ; , vaccinated.
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Third, children and adolescents (<20 years of age)
were more likely to have high anti-PT titres than
adults. The standardized relative prevalence of high-
titre sera in each country for those <20 years old
compared to those >20 years was 1.4 for The
Netherlands, 1.5 for Finland, 1.7 for East Germany,
2.3 for France, 3.0 for West Germany, 5.0 for United
Kingdom and 6.5 for Italy.
Fourth, the age-standardized proportion of high-
titre sera occurring in age groups older than 10 years
was higher in high-coverage countries compared to
low. Thus, Finland (92% of all high-titre sera), The
Netherlands (89%), France (84%) and East Germany
(72%) were higher than United Kingdom (65%),
West Germany (60%) and Italy (55%).
Fifth, the prevalence of high-titre sera was higher in
adolescents (10–19 years) compared to children (3–9
years) in the high-coverage countries. Thus in Finland
(7.1% in adolescents vs. 2.4% in children, P<0.001),
France (4.8% vs. 1.3%, P<0.001), The Netherlands
(1.7% vs. 0.9%, P=0.09), East Germany (5.8% vs.
2.7%, Fisher’s exact P=0.4). The reverse trend was
observed in the low-coverage countries : England &
Wales (2.6% in adolescents vs. 3.2% in children,
P=0.54), West Germany (3% vs. 4.8%, P=0.09) and
Italy (5.7% vs. 8.8%, P=0.02).
Finally, there were a signiﬁcantly larger proportion
of high-titre sera in the age-standardized total popu-
lation in those countries undertaking serosurveys in
the 12 months following an epidemic year compared
to those countries with no recent epidemic. The stan-
dardized prevalence of high-titre sera in countries
with recent epidemics was 2.1% in France, 3.2% in
Italy and 3.4% in Finland compared to 0.9% in the
non-epidemic Netherlands and 1.2% in the United
Kingdom. No surveillance data was available from
Germany to determine the epidemic year.
DISCUSSION
This article is the ﬁrst to compare the seroepidemi-
ology of pertussis infection in several European
countries. The approach outlined allows the quantiﬁ-
cation and comparison of the extent of pertussis
infection in a variety of populations with very diﬀer-
ent historical exposure to both vaccine and infection.
The results show that overall there are signiﬁcant le-
vels of high titres of anti-PT antibody in all age
groups in all the study populations, but with evidence
of both age- and country-speciﬁc diﬀerences. By col-
lating data on coverage levels, vaccine types and
schedules, a better understanding of the reasons be-
hind these inter- and intra-country diﬀerences can be
developed.
One of the main objectives of the ESEN project was
to standardize the methodology for serum bank col-
lection and testing [34]. Each country continued to use
their usual ELISA method to detect PT antibody,
which have been shown to diﬀer in several aspects
resulting in potential problems of comparison [26].
The distribution and testing of a reference panel of
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Fig. 2. Age-speciﬁc distribution of PT high IgG titres and
historical reported DTP3 coverage in three low coverage
ESEN countries. %, >125 units/ml ; , 62.5–125 units/ml ;
, vaccinated.
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sera allowed a process of statistical standardization
into a common unitage. As outlined earlier, standard-
ization was noted to be problematical for two part-
ners (The Netherlands, Germany). This suggests that
the levels of high titre presented in this paper may
represent an underestimate of the true situation for
these two countries and these results should be inter-
preted cautiously [26]. Bearing in mind these caveats,
on interpreting the data in relation to other data
sources, observed diﬀerences in the age-speciﬁc distri-
bution of titres do seem to represent real epidemi-
ological diﬀerences.
A high titre of anti-PT IgG antibody (>125 ESEN
units/ml) may be due to either recent infection and/or
exposure to a speciﬁc vaccine. The standardized
results from the clinical trials of a variety of acellular
Table 3. Post-vaccination PT IgG titres in ESEN units* for a variety of acellular and whole-cell vaccines and
estimated proportion of vaccines with PT IgG titres>125 ESEN units (adapted from Miller et al., Bell et al.
[24, 28–30]).
Type of
vaccine Manufacturer
Primary course Booster course
Age
(mo.)
PT GMT after
4–6 weeks
(estimated %
>125 units)
PT GMT after
12–18 mo.
(estimated %
>125 units)
Age
(yr)
PT GMT
after 4–6 weeks
(estimated %
>125 units)
Whole cell Wellcome 2, 3, 4 0.8 (0.9%) [28] 0.3 (0%) [28]
Whole cell Pasteur-Merieux 2, 3, 4 35.4 (26.1%) [29] —
Whole cell Wellcome 3, 5, 9 4–5 5.1 (1%) [30]
Acellular Pasteur-Me´rieux (now
Aventis-Pasteur)
2, 3, 4 33.9 (11%) [28] 2.1 (0.3%) [28] 4–5 28.1 (10.3%) [24]
Acellular Connaught 2, 3, 4 25.0 (1.8%) [28] 0.7 (0%) [28]
Acellular Lederle 3, 5, 9 3.9 (1.7%) [28] 0.2 (1.6%) [28]
Acellular SmithKline Beecham 2, 3, 4 4–5 20.9 (8.8%) [24]
Acellular Chiron Biocine 2, 3, 4 4–5 83.8 (36.7%) [24]
Acellular Wyeth-Lederle 2, 3, 4 4–5 11.1 (4.3%) [24]
* All assay results measured in arbitrary units by the Centre for Applied Microbiology and Research (CAMR). These were
converted to ESEN units.
Table 2. Vaccination programme performance, inter-epidemic period by decade and% of reported cases>10 years
of age in six ESEN countries
Group 1: High-coverage countries Group 2: Low-coverage countries
Finland France
East
Germany
The
Netherlands
England
& Wales
West
Germany Italy
Mean primary
DPT3* coverage
by decade
1970–1979 n.a. n.a. y95% 96% 59% n.a. 16%
1980–1989 y99% y85% y95% 97% 62% 0% 22%
1990–1999 99% 95% 85% 97% 92% 85% 53%
Inter-epidemic period
and % of cases
>10 years old
1970–1979 >10 yr (n.a.) 4 yr (n.a.) 4 yr (n.a.) n.a. 4 yr (8%) n.a. 4 yr (9%)
1980–1989 7 yr (n.a.) 4 yr (n.a.)>10 yr (n.a.) n.a. 4 yr (8%) n.a. 4 yr (6%)
1990–1999 4–5 yr (59%) 4 yr (n.a.) n.a. 4 yr (24%) 5 yr (18%) n.a. 4 yr (14%)
* Mean reported coverage of three doses of diphtheria-tetanus-pertussis (DPT) vaccine by 12–24 months of age.
n.a., Not available.
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and whole-cell vaccines showed that in all cases 12–18
months after the primary course (and in 3 out of
5 vaccines at the peak anti-PT antibody response by
4–6 weeks), the estimated proportion of vaccinees
with titres>125 units/ml was<2%. Between 4 and 6
weeks after a booster dose of the whole-cell vaccine
at 4–5 years of age, the estimated proportion of vac-
cinees with titres >125 units was 1%, but much
higher for all four examined acellular vaccines. It
seems probable that the proportion with titres above
125 units/ml will have declined to very low levels after
1–2 years. Several countries had a booster dose in the
routine immunization programme in the second year
of life at the time of the serosurvey, but none had a
further booster dose for older age groups (the ado-
lescent acellular booster in France only had an esti-
mated coverage of only 3%). Thus the observation of
high-titre sera in age cohorts older than 2 years can be
considered with high probability to indicate infection
with pertussis in the previous 12 months. As demon-
strated by de Melker, a signiﬁcant proportion of these
individuals will have had mild or asymptomatic
infection compared to classical clinical symptoms of
pertussis [25]. For those under 2 years the situation
is more complex, particularly in the case of those
countries delivering acellular vaccines known to lead
to high anti-PT titres (France, Germany, Italy). High-
titre sera in these age groups could thus represent
either recent infection or vaccination.
The observation that high-titre sera are more likely
in older age groups in those countries with a history of
high immunization coverage compared to low cover-
age correlates with the age distribution of clinical
cases reported by the routine surveillance systems.
This suggests that a more sensitive surveillance system
due to improved diagnostic tools does not provide the
sole explanation for the recent observed increase in
reported pertussis cases in adolescents and adults in
highly vaccinated populations. Rather this represents
a real epidemiological observation, reﬂecting partly a
reduction in transmission due to increasing vaccine
coverage of age cohorts and partly waning immunity.
Indeed, the ﬁnding of widespread circulation of
pertussis in the various populations has several ex-
planations. One is a failure to achieve adequate levels
of coverage with the primary schedule, while others
are primary vaccine failure (PVF) and secondary
vaccine failure (SVF).
Role of low coverage
Italy and Germany had the highest proportion in the
0–2 years age group with high-titre sera compared to
the other countries. Both countries had just intro-
duced acellular vaccines into their routine program-
mes, some of which produce a high anti-PT titre
complicating the seroproﬁle interpretation. It is thus
impossible to disentangle the proportion of high-titre
sera due to recent infection and the proportion due to
recent vaccination in this age group. However, older
children were more likely to have high-titre sera
compared to adolescents, which corresponds to the
observed age distribution of cases in low-coverage
countries. This suggests that the priority in these
countries should be to strengthen delivery of the pri-
mary vaccination programme, rather than introduce
additional booster doses.
Role of PVF
Ongoing circulation in highly vaccinated populations
can occur due to vaccine failure – which may be pri-
mary or secondary. PVF represents a failure of initial
seroconversion. Factors of relevance for pertussis
vaccine PVF include the type of vaccine, the number
0
0 21
10
–1
4
15
–1
9
3–
9
20
–2
4
25
–3
4
35
–4
4
45
–6
4
65
+
5
10
15
20
25
Age group (years)
0 21
10
–1
4
15
–1
9
3–
9
20
–2
4
25
–3
4
35
–4
4
45
–6
4
65
+
Age group (years)
Pr
op
or
tio
n 
of
 p
op
ul
at
io
n
>
12
5 
un
its
/m
l
0
5
10
15
20
25
Pr
op
or
tio
n 
of
 p
op
ul
at
io
n
>
12
5 
un
its
/m
l
Netherlands
France
East Germany
Finland
England
West Germany
Italy
(a)
(b)
Fig. 3.Age-speciﬁc distribution of PT IgG high titres (>125
ESEN units) in (a) four high-coverage and (b) three low-
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of doses (with three doses more immunogenic than
two) and age at vaccination [35]. It is possible to
compare the impact of accelerated and non-
accelerated programmes. Both Finland and The
Netherlands had achieved very high historical vacci-
nation coverage levels with a non-accelerated whole-
cell primary vaccine programme and a booster dose
for <2-year-olds. Both had the lowest observed pro-
portion of high-titre sera in <2-year-olds compared
to other countries. The protection imparted by the
non-accelerated programme in The Netherlands is
diﬃcult to evaluate, as an epidemic occurred after the
serosurvey was completed, however, the serosurvey
was conducted in Finland following an epidemic year
and minimal high-titre sera were evident in those
<2 years of age. Two counties had an accelerated
programme (United Kingdom, France). In France,
high-titre sera were observed in infants, however as
outlined a proportion may be vaccine-induced. In the
United Kingdom, although the serosurvey took place
after a prolonged non-epidemic period, high-titre sera
(2%) were observed in those 1–2 years of age, with no
data available for those under 12 months old. This
suggests that an accelerated programme may be less
eﬀective than a non-accelerated programme (due
perhaps to a higher PVF rate). Comparisons of the
impact of accelerated and non-accelerated primary
schedules need to be further explored.
Role of SVF
SVF represents waning immunity after initial docu-
mented seroconversion and could explain the recent
observations of a resurgence of pertussis in the highly
vaccinated populations of The Netherlands and
Finland. Indeed our study conﬁrms published evi-
dence that vaccinated persons become increasingly
susceptible to infection 5–10 years following vacci-
nation [17, 36]. In Finland there has been high vaccine
coverage with whole-cell vaccine for over 20 years,
with a large reduction in reported incidence, and
decreased opportunity for natural boosting. Our
study demonstrates that a large proportion of teen-
agers and adults in Finland were recently infected
with pertussis ; an observation matched by the clinical
surveillance system. Similar observations were also
seen in France and East Germany – other countries
that have had high pertussis vaccine coverage for
several decades.
In the highly vaccinated Netherlands, although the
majority of high-titre sera occurred in those older
than 10 years of age, the extent of observed circu-
lation of pertussis in the population was considerably
less than in Finland. The observed high-titre sero-
proﬁle represents the circulation of pertussis in only
the previous 12 months, rather than the susceptibility
of the population. The population immunity was
presumably low, as a large pertussis outbreak did
occur in The Netherlands in the months after the
serosurvey was completed, with high attack rates
particularly in infants [2]. One explanation proposed
for the outbreak was the emergence of antigenic
changes in circulating strains [2, 3], such that protec-
tion induced by the Dutch whole-cell vaccine was
reduced. Alternatively, anti-PT antibody levels have
recently been shown to correlate with partial protec-
tion against clinically typical pertussis infection [37,
38]. Indeed, the serosurvey demonstrates that the
highest proportion of those <2 years of age sero-
negative for anti-PT amongst all countries was in The
Netherlands, suggesting reduced protection against
clinically typical infection in the Dutch population.
Variation in vaccine eﬀectiveness for locally produced
vaccines (particularly whole-cell vaccine) has been
reported [39–41].
The present study also provides evidence of waning
protection after natural infection, as all countries
showed evidence of recent infection in those older
than 40 years of age; a group most likely to have
acquired natural immunity during childhood. This
observation agrees with previous studies in non-
vaccinated populations, suggesting that adults can be
susceptible to symptomatic re-infection approxi-
mately 20 years after the ﬁrst pertussis episode [13].
Burden of infection and role in transmission
We are unable to determine the clinical severity of
these infections in this study. From a disease burden
perspective, recent studies ﬁnd that the majority of
cases of adult infection result in mildly symptomatic
disease [25]. However, infection in adults has been
suggested to be of relevance in terms of transmission
to younger age groups [42], particularly in areas with
high vaccine coverage [21]. We were unable to esti-
mate from this study the contribution of older in-
dividuals with high titre to disease transmission.
However, we did ﬁnd that although all high-coverage
countries had evidence of adult and adolescent infec-
tion, in only one country (France) was a high pro-
portion of high-titre sera found in infancy (and a large
proportion of this may be due to the immunogenic
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vaccine). Further comparative work, for example with
hospitalization data, needs to be undertaken to better
describe the burden of disease in infancy over time
and the role of adults and adolescents in disease
transmission.
Recent programmatic changes
Due to concerns about the reappearance of pertussis,
programme changes have been implemented in many
of the countries since the serosurveys were completed.
To provide direct protection to infants at a younger
age and narrow the window of risk, The Netherlands
(in addition to France and the United Kingdom)
introduced an accelerated schedule in 1999. In an at-
tempt to tackle the perceived role of older children
and adolescents in transmission of pertussis to younger
age groups, several countries have introduced acellular
booster doses for older age groups: four at pre-
school age (Finland, Italy, The Netherlands, United
Kingdom) and in adolescents in Germany. The
methodology used in this paper will be a useful tool to
compare the impact of these alternative vaccination
strategies on pertussis circulation in the population.
In conclusion, this study demonstrates a novel
approach to explore the epidemiology of pertussis
infection and to evaluate the impact of a variety of
interventions. The study found evidence of signiﬁcant
circulation of pertussis in all age groups in a wide
selection of populations (from poorly to highly
vaccinated). There were large diﬀerences in the
apparent eﬀectiveness of national programmes with
evidence of more circulation in older age groups in
highly vaccinated populations. Programme eﬀective-
ness in higher coverage countries seems to be depen-
dent on several factors including type of vaccine used,
age of ﬁrst vaccination and the presence of booster
doses. It is unclear what will be the impact of the
introduction of booster doses in older groups on
transmission to younger at-risk age groups. These
interventions will need to be evaluated closely and
compared carefully with strategies that attempt to
provide direct protection to the highest risk popu-
lation – the young infant.
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APPENDIX. Number of sera tested per country, year of testing and % of sera>125 units
Age
(years)
Finland
1996
France
1998
West
Germany
1995
East
Germany
1995
Italy
1996
The
Netherlands
1995
England
& Wales
1996
No.
of
sera
%
>125
units
No.
of
sera
%
>125
units
No.
of
sera
%
>125
units
No.
of
sera
%
>125
units
No.
of
sera
%
>125
units
No.
of
sera
%
>125
units
No.
of
sera
%
>125
units
<1 100 0 70 4.3 45 13.3 50 4 78 11.5 202 0.5 0 —
<2 100 0 86 1.2 56 21 50 10 89 19.1 192 0 90 2.2
<3 81 1.2 88 8 58 8.6 31 0 89 10.1 158 0 87 2.3
3–9 674 2.4 600 1.3 587 4.8 111 2.7 628 8.8 921 0.9 682 3.2
10–14 497 6.4 386 6.5 396 2.5 103 2.9 476 6.5 578 2.4 449 2.7
15–19 471 7.9 469 3.4 428 3.5 69 10.1 509 5.1 453 0.9 155 2.6
20–24 200 4 265 4.2 201 5 42 4.8 243 3.7 339 1.2 27 0
25–34 400 3.3 403 1.7 380 2.9 42 0 367 1.1 810 1.2 239 0.4
35–44 352 2 312 1.6 286 2.4 19 0 302 0.7 981 0.5 360 0.6
45–64 388 3.3 494 1 346 0.3 17 0 399 0.5 2009 0.8 358 0.3
65+ 118 2.5 279 0.7 156 0.6 2 0 96 2.1 1112 0.5 192 1.6
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